Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Furegrelate sodium (U-63557A) is a selective thromboxane synthase inhibitor with oral activity. Furegrelate sodium(U-63557A) inhibits thromboxane A2 (TXA2) synthase in human platelet microsomes with an IC50 of 15 nM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 74.00 | |
5 mg | In stock | $ 178.00 | |
10 mg | In stock | $ 297.00 | |
25 mg | In stock | $ 492.00 | |
50 mg | In stock | $ 718.00 | |
100 mg | In stock | $ 987.00 | |
500 mg | In stock | $ 1,980.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 108.00 |
Description | Furegrelate sodium (U-63557A) is a selective thromboxane synthase inhibitor with oral activity. Furegrelate sodium(U-63557A) inhibits thromboxane A2 (TXA2) synthase in human platelet microsomes with an IC50 of 15 nM. |
Targets&IC50 | TXA2R:15 nM |
In vivo | Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme.Furegrelate Sodium ?(1-5 mg/kg; Oral) prevents blockage of the coronary artery. Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation. Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature. |
Synonyms | U-63557A |
Molecular Weight | 275.23 |
Formula | C15H10NNaO3 |
CAS No. | 85666-17-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (36.33 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Furegrelate sodium 85666-17-7 DNA Damage/DNA Repair Metabolism PPAR arteries hypertension available Furegrelate inhibit orally antiplatelet platelet arterial human stenosed U-63557A Inhibitor pulmonary coronary inhibitor